07.20.23
Rank: #26 (Last year: #25)
¥611.1 Billion ($4.61 Billion)
Prior Fiscal: ¥533.8 Billion
Percentage Change: +14.5%
R&D Expenditure: ¥154.1B (total)
Best FY22 Quarter: Q4 ¥176.1B
Latest Quarter: Q4 ¥176.1B
No. of Employees: 73,878 (total)
Global Headquarters: Minato-ku, Tokyo, Japan
KEY EXECUTIVES:
Kenji Sukeno, Chairman, Director & Board Chairman, FUJIFILM Holdings Corporation
Teiichi Goto, President, Representative Director & CEO, FUJIFILM Holdings Corporation
Masayuki Higuchi, Director, CFO, FUJIFILM Holdings Corporation
Masataka Akiyama, Representative Director, Chairman & CEO, FUJIFILM Healthcare Corporation
Akio Yamamoto, Representative Director, President & COO, FUJIFILM Healthcare Corporation
Henry Izawa, President & CEO, FUJIFILM Healthcare Americas Corporation
During the summer of 2020, cancer informatics and digital pathology solution provider Inspirata announced it was partnering with Fujifilm to distribute and service the former’s digital pathology workflow software. Digital pathology is the digitization of pathology slides to conduct software visualization analysis of a specimen rather than using microscopic slides. The arrangement was made for the worldwide marketplace, and came with exclusivity within the U.K., Italy, Spain, Portugal, Belgium, the Netherlands, and Luxembourg.
Inspirata’s scanner-agnostic solution made for a good match for Fujifilm’s technology, bridging a technical gap between pathology, radiology, and oncology. The company’s respective systems Synapse (Fujifilm) and Dynamyx (Inspirata) integrated well together, enabling a seamless solution for customers.
Fast-forward to the close of the 2022 calendar year and it was announced Fujifilm was to acquire the assets of Inspirata’s Dynamyx digital pathology business, moving customers and employees over to the Japanese-based firm. Much of the industry still relies on analog solutions for pathology, so the opportunity for growth for Fujifilm with the buy was significant.
“Since launching our European partnership with Inspirata three years ago, we’ve seen great success implementing our combined technologies in several healthcare organizations, notably in the U.K.,” explained Masa Fukumoto, managing director, FUJIFILM Healthcare Europe and senior vice president, FUJIFILM Medical Systems Europe. “We’ve received feedback from customers anticipating digitizing pathology will be the most transformative thing they do for their practice, and we look forward to continuing our global expansion.”
Approximately a month later, the deal was closed. The creation of a digital pathology division expands Fujifilm’s Synapse Enterprise Imaging offering to enable the digitization and integration of pathology images and data into a healthcare organization’s electronic health record system and to help streamline care delivery for oncology patients and provider teams.
The Synapse Enterprise Imaging system enables healthcare organizations to allow staff to take advantage of real-time, cross-departmental collaboration with views of the entire patient. It features a number of capabilities for different clinical areas under a single umbrella product. In addition to the aforementioned Pathology PACS solution, other offerings include Cardiovascular Select; PACS for Enterprise, Radiology, and Cardiology; Vendor-Neutral Archive; and more.
The addition of the Pathology offering wasn’t the only improvement to the system. In November, Fujifilm announced it had released Synapse 7.2, the newest version of its Synapse 7x enterprise picture archiving and communication system (PACS). This product unites radiology, mammography, cardiology, and enterprise imaging on an all-encompassing, server-side rendering, cloud deployable, diagnostic PACS viewer. Version 7.2 delivers more than 80 new workflow features and advanced toolsets to enhance the efficiency of clinical radiology and cardiology users, as well as IT professionals.
Another addition to the system was the incorporation of Synapse Analytics, a cloud-based data mining extraction engine that enables healthcare organizations to analyze business data to see current and predictive views of their business operations. The secure and customizable software engine provides tracking and insights of trends in procedure volume, patient population analysis, lab operation efficiency, profitability, and diagnostic accuracy. Further, the Analytics product could be applied throughout the Synapse portfolio, bringing analytics capabilities to healthcare providers and administrators across the enterprise.
Synapse also gained credibility from an independent source—the U.S. Department of Defense (DoD)—when it awarded a Pacific Air Force/ Navy (PACAF) contract to the organization for its software product. The contract was given to incorporate the Synapse PACS system into U.S. Naval and Air Force medical treatment facilities’ PACS. According to Fujifilm, it was the DoD’s vendor of choice for this award due to Synapse PACS’s ability to strengthen government healthcare operations through robust integrations with imaging modalities, improved system services, and enhanced image distribution for clinical users across 14 U.S. Naval and Air Force medical treatment facilities. The following criteria established by the U.S. government for PACS vendor selection were met:
In addition, the company launched the FDR Cross—a hybrid C-arm and portable X-ray for hospitals and ambulatory surgery centers—in the U.S. According to Fujifilm, the dual-function C-arm is the first of its kind to offer portable fluoroscopic and radiographic imaging on one platform, reducing the need to bring in additional imaging equipment for essential image-guided procedures.
Fujifilm also gained FDA 510(k) clearance for the EG-740UT linear endoscopic ultrasound scope (EUS), which is compatible with its ARIETTA 850 ultrasound processor. The EUS scope was designed for diagnostic and therapeutic endoscopic ultrasound procedures in the upper digestive tract.
In November, the firm announced the U.S. launch of the SCENARIA View Focus Edition Computed Tomography system—a scanner with an advanced Cardiac Motion Correction feature, called Cardio StillShot. The system is designed for routine and advanced clinical applications, including coronary computed tomography angiography, interventional CT, extended coverage shuttle scanning for perfusion exams, and dual energy examinations.
The company will lean heavily on these innovations to continue the growth trajectory it enjoyed during its latest fiscal year. The Medical Systems segment of Fujifilm Healthcare accounted for two-thirds of total sales revenue for the unit. It contributed ¥611.1 billion to the company’s coffers, reflecting a rise of over 14%, while the entire Healthcare segment tallied ¥917.9 billion.
¥611.1 Billion ($4.61 Billion)
Prior Fiscal: ¥533.8 Billion
Percentage Change: +14.5%
R&D Expenditure: ¥154.1B (total)
Best FY22 Quarter: Q4 ¥176.1B
Latest Quarter: Q4 ¥176.1B
No. of Employees: 73,878 (total)
Global Headquarters: Minato-ku, Tokyo, Japan
KEY EXECUTIVES:
Kenji Sukeno, Chairman, Director & Board Chairman, FUJIFILM Holdings Corporation
Teiichi Goto, President, Representative Director & CEO, FUJIFILM Holdings Corporation
Masayuki Higuchi, Director, CFO, FUJIFILM Holdings Corporation
Masataka Akiyama, Representative Director, Chairman & CEO, FUJIFILM Healthcare Corporation
Akio Yamamoto, Representative Director, President & COO, FUJIFILM Healthcare Corporation
Henry Izawa, President & CEO, FUJIFILM Healthcare Americas Corporation
During the summer of 2020, cancer informatics and digital pathology solution provider Inspirata announced it was partnering with Fujifilm to distribute and service the former’s digital pathology workflow software. Digital pathology is the digitization of pathology slides to conduct software visualization analysis of a specimen rather than using microscopic slides. The arrangement was made for the worldwide marketplace, and came with exclusivity within the U.K., Italy, Spain, Portugal, Belgium, the Netherlands, and Luxembourg.
Inspirata’s scanner-agnostic solution made for a good match for Fujifilm’s technology, bridging a technical gap between pathology, radiology, and oncology. The company’s respective systems Synapse (Fujifilm) and Dynamyx (Inspirata) integrated well together, enabling a seamless solution for customers.
Fast-forward to the close of the 2022 calendar year and it was announced Fujifilm was to acquire the assets of Inspirata’s Dynamyx digital pathology business, moving customers and employees over to the Japanese-based firm. Much of the industry still relies on analog solutions for pathology, so the opportunity for growth for Fujifilm with the buy was significant.
“Since launching our European partnership with Inspirata three years ago, we’ve seen great success implementing our combined technologies in several healthcare organizations, notably in the U.K.,” explained Masa Fukumoto, managing director, FUJIFILM Healthcare Europe and senior vice president, FUJIFILM Medical Systems Europe. “We’ve received feedback from customers anticipating digitizing pathology will be the most transformative thing they do for their practice, and we look forward to continuing our global expansion.”
Approximately a month later, the deal was closed. The creation of a digital pathology division expands Fujifilm’s Synapse Enterprise Imaging offering to enable the digitization and integration of pathology images and data into a healthcare organization’s electronic health record system and to help streamline care delivery for oncology patients and provider teams.
The Synapse Enterprise Imaging system enables healthcare organizations to allow staff to take advantage of real-time, cross-departmental collaboration with views of the entire patient. It features a number of capabilities for different clinical areas under a single umbrella product. In addition to the aforementioned Pathology PACS solution, other offerings include Cardiovascular Select; PACS for Enterprise, Radiology, and Cardiology; Vendor-Neutral Archive; and more.
The addition of the Pathology offering wasn’t the only improvement to the system. In November, Fujifilm announced it had released Synapse 7.2, the newest version of its Synapse 7x enterprise picture archiving and communication system (PACS). This product unites radiology, mammography, cardiology, and enterprise imaging on an all-encompassing, server-side rendering, cloud deployable, diagnostic PACS viewer. Version 7.2 delivers more than 80 new workflow features and advanced toolsets to enhance the efficiency of clinical radiology and cardiology users, as well as IT professionals.
Another addition to the system was the incorporation of Synapse Analytics, a cloud-based data mining extraction engine that enables healthcare organizations to analyze business data to see current and predictive views of their business operations. The secure and customizable software engine provides tracking and insights of trends in procedure volume, patient population analysis, lab operation efficiency, profitability, and diagnostic accuracy. Further, the Analytics product could be applied throughout the Synapse portfolio, bringing analytics capabilities to healthcare providers and administrators across the enterprise.
Synapse also gained credibility from an independent source—the U.S. Department of Defense (DoD)—when it awarded a Pacific Air Force/ Navy (PACAF) contract to the organization for its software product. The contract was given to incorporate the Synapse PACS system into U.S. Naval and Air Force medical treatment facilities’ PACS. According to Fujifilm, it was the DoD’s vendor of choice for this award due to Synapse PACS’s ability to strengthen government healthcare operations through robust integrations with imaging modalities, improved system services, and enhanced image distribution for clinical users across 14 U.S. Naval and Air Force medical treatment facilities. The following criteria established by the U.S. government for PACS vendor selection were met:
- PACS to effectively integrate with voice recognition/dictation system, provide a solution for critical test result management, and multi-site region-wide peer review for radiologists on their PACS workstations.
- PACS to seamlessly integrate with the Army and Navy Enterprise Clinical Imaging Archive and the Air Force’s Data Center Image Repositories.
In addition, the company launched the FDR Cross—a hybrid C-arm and portable X-ray for hospitals and ambulatory surgery centers—in the U.S. According to Fujifilm, the dual-function C-arm is the first of its kind to offer portable fluoroscopic and radiographic imaging on one platform, reducing the need to bring in additional imaging equipment for essential image-guided procedures.
Fujifilm also gained FDA 510(k) clearance for the EG-740UT linear endoscopic ultrasound scope (EUS), which is compatible with its ARIETTA 850 ultrasound processor. The EUS scope was designed for diagnostic and therapeutic endoscopic ultrasound procedures in the upper digestive tract.
In November, the firm announced the U.S. launch of the SCENARIA View Focus Edition Computed Tomography system—a scanner with an advanced Cardiac Motion Correction feature, called Cardio StillShot. The system is designed for routine and advanced clinical applications, including coronary computed tomography angiography, interventional CT, extended coverage shuttle scanning for perfusion exams, and dual energy examinations.
The company will lean heavily on these innovations to continue the growth trajectory it enjoyed during its latest fiscal year. The Medical Systems segment of Fujifilm Healthcare accounted for two-thirds of total sales revenue for the unit. It contributed ¥611.1 billion to the company’s coffers, reflecting a rise of over 14%, while the entire Healthcare segment tallied ¥917.9 billion.